EUCOPE Resources / News - May 10, 2022
As the science around genomics continues to evolve, advanced diagnostics technologies are delivering benefits to today’s patients while supporting future research and clinical development. However, beyond research programmes, many of these technologies are not reaching patients in clinical routine care in Europe. Patients’ health outcomes… read more
EUCOPE Resources / News / Press Releases - April 27, 2022
EUCOPE’s latest position paper outlines our vision for the evolution of the EU Regulatory framework and a modernisation of the Centralised Procedure to ultimately bring novel medicines earlier to patients. The European Centralised Procedure (CP) has helped and accelerated the approval of novel medicines across… read more
EUCOPE Resources / Events & Meetings / News - October 18, 2021
EUCOPE, in partnership with Sanofi, participated in the European Health Forum Gastein 2021 (EHFG) on 29 September in a session on rare diseases to discuss what is needed to stimulate basic research, clinical development, and access to care across the EU in light of the… read more
EUCOPE Resources / News / Press Releases - July 29, 2021
The European Commission is consulting stakeholders as part of its revision process of two major pieces of legislation, on medicines for rare diseases and paediatric patients. Central to the development of innovative treatments for these specific categories of patients, this revision process represents an important… read more
EUCOPE Resources - July 8, 2021
The complexities related to delivering some Advanced Therapy Medicinal Products (ATMPs) most likely will require highly specialized clinical expertise and infrastructures, which currently do not exist in all EU counties. Therefore, relocating or crossing borders often represent the only solution for many patients. A well-developed… read more
EUCOPE Resources / News / Press Releases - April 27, 2021
The Genomics Working Group is made up of advanced diagnostics companies that have come together to ensure Europe will be able to draw benefit from the significant advances that have been made in genomic testing. The group aims to facilitate a dialogue around these technologies… read more
EUCOPE Resources / Press Releases - January 7, 2021
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies submitted its response to the Paediatric and Orphan Medicinal Products (OMPs) inception impact assessment. EUCOPE represents 130 companies, many focused on rare diseases, largely small to medium-sized, playing a key role… read more
EUCOPE Resources / News - December 1, 2020
EUCOPE’s approach to the EU environment for the development of OMPs On 11 August 2020, the European Commission published its evaluation on the legislation for medicines for rare diseases and for children. In November this was followed by an Inception Impact Assessment outlining policy options… read more
EUCOPE Resources / News / Press Releases - November 25, 2020
EUCOPE, the European association for small to medium-sized companies active in pharmaceuticals and biotechnologies – many of which are researching and developing rare disease treatments – notes the publication of the European Commission Communication on the Pharmaceutical Strategy for Europe. EUCOPE calls for a comprehensive Pharmaceutical Strategy… read more
EUCOPE Resources / News - May 15, 2020
The 10th European Conference on Rare Diseases (ECRD), the largest patient-led event on rare diseases and orphan products, presented an excellent opportunity for exchange among the patient community and experts from various backgrounds. The conference allowed EUCOPE to share the key findings of the study… read more
